HOME COMPANY PORTFOLIO INVESTOR RELATIONS MEDIA CONTACT PRESS RELEASES 2017-09-13 Karolinska Development's portfolio company Umecrine Cognition presents positive phase 1b data for its drug candidate against hepatic encephalopathy 2017-09-13 Karolinska Development's portfolio company BioArctic intends to list on Nasdaq Stockholm 2017-08-31 Change of Number of Shares and Votes in Karolinska Development NEWS 2017-09-14 Karolinska Developments's portfolio company Modus Therapeutics recruits new Chief Medical Officer 2017-09-05 Karolinska Development company Umecrine Cognition appoints Dr. Thomas P. Blackburn to its board of directors 2017-08-02 Karolinska Development company Aprea Therapeutics announces First Patient Enrolled in Phase Ib/II Clinical Study FINANCIAL REPORTS Q2 Report 2017 Annual Report 2016 © 2015 Karolinska Development AB (publ) Registered office: Solna, Sweden | Org. no. 556707-5048 | Contact: info@karolinskadevelopment.com Legal notice